AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer

• Published in: Cancers Vol. 14; no. 3; p. 809
• Main Authors: Hojnik, Marko, Šuster, Nataša Kenda, Smrkolj, Špela, Sisinger, Damjan, Grazio, Snježana Frković, Verdenik, Ivan, Rižner, Tea Lanišnik
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 05-02-2022; MDPI
• Subjects: Apoptosis; Biomarkers; Cell differentiation; Chemotherapy; Kinases; Mutation; Ovarian cancer; Paraffin; United Kingdom > UK; United States > US; Switzerland; high-grade serous ovarian cancer; aldo-keto reductase family 1 member B1 (AKR1B1); survival; aldo-keto reductase family 1 member B10 (AKR1B10); immunohistochemistry; biomarker; prognosis; resistance
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14030809

Although aldo-keto reductases (AKRs) have been widely studied in cancer, no study to date has examined the roles of AKR family 1 members B1 (AKR1B1) and B10 (AKR1B10) in a large group of ovarian cancer patients. AKR1B1 and AKR1B10 play a significant role in inflammation and the metabolism of different chemotherapeutics as well as cell differentiation, proliferation, and apoptosis. Due to these functions, we examined the potential of AKR1B1 and AKR1B10 as tissue biomarkers. We assessed the immunohistochemical levels of AKR1B1 and AKR1B10 in tissue paraffin sections from 99 patients with high-grade serous ovarian cancer (HGSC) and compared these levels with clinicopathological characteristics, survival, and response to chemotherapy. A higher immunohistochemical AKR1B1 expression correlated with a better overall and disease-free survival of HGSC patients whereas AKR1B10 expression did not show any significant differences. A multivariant Cox analysis demonstrated that a high AKR1B1 expression was an important prognostic factor for both overall and disease-free survival. However, AKR1B1 and AKR1B10 were not associated with different responses to chemotherapy. Our data suggest that AKR1B1 is involved in the pathogenesis of HGSC and is a potential prognostic biomarker for this cancer.